Bienvenido al ::: SerTox :::!

     Menú
· Noticias
· Institucional
· Investigación
· Materiales Educativos
· Biblioteca multimedia
· Preguntas frecuentes
· Boletín
· Buscar
· Contáctenos
· Enlaces - Directorio
· Glosario
· Noticias x Mes
· Temas
· Top 15

EnglishSpanish

     Buscar


     Categorías
· Todas las Categorías
· Aportes
· Ejercicios
· Informan / Escriben
· La prensa
· Noticias del Sertox
· Recomendamos
· Toxicología al día
· Trivia toxicológica
· zNo sólo de tóxicos

     Blogs



     Manifiesto amianto





 Toxicología al día: Pharmaceutical industry off-label promotion and self-regulation in UK

Ver Imagen

Assorted pharmaceuticals (Foto: WP)

Pharmaceutical industry self-regulation of off-label drug promotion in the UK. eurekalert.org. January 26, 2016. The UK's self-regulatory approach to preventing pharmaceutical companies from promoting off-label use of their drugs detects mainly high-visibility promotional activity such as print advertising, according to a document analysis of off-label promotion rulings published this week in PLOS Medicine by Shai Mulinari and colleagues at Lund University, Sweden, and King's College London, UK. The study indicates that the UK self-regulatory approach is less capable of uncovering complex marketing campaigns than the government-led approach in the US.

n the US, the Food and Drug Administration (FDA) regulates and prosecutes off-label promotion, but legal actions against companies can also be brought by federal and state prosecutors, often following whistleblower (company insider) complaints facilitated by the False Claims Act. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has delegated this responsibility to a self-regulatory body set up by the pharmaceutical industry--the Prescription Medicines Code of Practice Authority (PMCPA). In this review of 74 off-label promotion rulings made by the PMCPA between 2003 and 2012, Mulinari and colleagues compare off-label promotion cases from the UK with whistleblower-initiated cases from the US. They find that while several US whistleblower-initiated cases alleged multifaceted and covert marketing campaigns, UK rulings described a more restricted range of promotional activities and typically referred to a single advertisement. The UK rulings cited efforts to expand drug use to unapproved indications (50%), diseases (39%) and dosing strategies (38%); competing companies lodged the majority (57%) of complaints whereas prescribers (the prime target of off-label promotion) lodged only 22% of the complaints. Almost half of the 43 violating companies were found to have promoted products off-label more than once in the UK, and about one-fourth were ruled in breach three or more times.

The study describes PMCPA rulings and whistleblower-initiated US cases, and therefore provides an incomplete view of off-label marketing in the UK and US. However, the results suggest that the UK's self-regulatory mechanism for detecting, deterring, and sanctioning off-label promotion may be inadequate. The authors state, "UK authorities should consider introducing increased incentives and protections for whistleblowers combined with US-style governmental investigations and meaningful sanctions. UK prescribers should be attentive to, and increasingly report, off-label promotion."

###

Research Article

Funding:

This work was supported by the Swedish Research Council, http://www.vr.se [grant 2013-1268 to SM], and Riksbankens Jubileumsfond (Bank of Sweden Tercentenary Foundation), http://www.rj.se [grant P09-0281:1-E to SM]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

AV and CD are members of Health Action International (HAI), a non-profit organisation working to increase access to essential medicines and the rational use of medicines. HAI has undertaken work, with the WHO, on a teaching manual for medical and pharmacy students, 'Understanding and Responding to Pharmaceutical Promotion'.

Citation:

Vilhelmsson A, Davis C, Mulinari S (2016) Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012. PLoS Med 13(1): e1001945. doi:10.1371/journal.pmed.1001945

Enviado por jcp el 26 enero 2016 00:00:00 (137 Lecturas)






Artículos e imágenes de:
Aspectos históricos legales regulatorios
Aspectos históricos legales regulatorios
 Medicamentos
Medicamentos
 Unión Europea
Unión Europea

 
     Enlaces Relacionados


Noticia más leída sobre Aspectos históricos legales regulatorios:
Restricción al piroxican, toxina botulínica, y más.


     Votos del Artículo
Puntuación Promedio: 0
votos: 0

Por favor tómate un segundo y vota por este artículo:

Excelente
Muy Bueno
Bueno
Regular
Malo


     Publicidad






Todos los logos y marcas registradas son propiedad de sus respectivos dueños. Los comentarios son propiedad de quienes lo envían, todo el resto © 2006-2011 by Sertox.

Webs Asociadas: www.country2.com / Radio FM Estacion San Pedro / Lombó Teatro Salamanca - Zamora

PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.
Página Generada en: 0.22 Segundos